Can Alternate Day Fasting Help Reverse Liver Disease? Insights from the FAST Trial
- Conditions
- Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified
- Registration Number
- CTRI/2024/06/069119
- Lead Sponsor
- Intitute of Liver and BIliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
NASH patients, Age 18-65 years. BMI 25-40kg/m3, and CAP more than 290. Stable weight in the last 3 months prior to enrolling in the study(less than 5kg weight variation). Imaging showed steatotic liver disease, liver stiffness less than 14kPa measured by fibroscan. Histologically proven NASH/MASH, fibrosis up to F3. Subjects willing to participate in the study
Liver stiffness more than 14kPa measured by fibroscan or Fibrosis more than F3. Diabetes with HbA1c more than 8.5%. Patients with another co-existing active liver disease e.g. hepatitis B or C, alcoholic liver disease. Patients with cirrhosis, HCC, or other malignancy. Chronic kidney disease, cardiovascular disorders, uncontrolled hypertension. Chronic infections, chronic inflammatory diseases. Patients on weight loss medications e.g semaglutide. Pregnant or lactating women and those planning a pregnancy. A patient who is not willing to participate in the study, or failed to provide the consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method